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Abstract
Activating mutations in the kinase domain of anaplastic lymphoma kinase (ALK) have recently been shown to be an
important determinant in the genetics of the childhood tumor neuroblastoma. Here we discuss an in-depth anal-
ysis of one of the reported gain-of-function ALK mutations—ALKI1250T—identified in the germ line DNA of one
patient. Our analyses were performed in cell culture–based systems and subsequently confirmed in a Drosophila
model. The results presented here indicate that the germ line ALKI1250T mutation is most probably not a determi-
nant for tumor initiation or progression and, in contrast, seems to generate a kinase-dead mutation in the ALK
receptor tyrosine kinase (RTK). Consistent with this, stimulation with agonist ALK antibodies fails to lead to stim-
ulation of ALKI1250T and we were unable to detect tyrosine phosphorylation under any circumstances. In agree-
ment, ALKI1250T is unable to activate downstream signaling pathways or to mediate neurite outgrowth, in
contrast to the activated wild-type ALK receptor or the activating ALKF1174S mutant. Identical results were obtained
when the ALKI1250T mutant was expressed in a Drosophilamodel, confirming the lack of activity of this mutant ALK
RTK. We suggest that the ALKI1250T mutation leads to a kinase-dead ALK RTK, in stark contrast to assumed gain-of-
function status, with significant implications for patients reported to carry this particular ALK mutation.
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Introduction
During 2008, anaplastic lymphoma kinase (ALK) receptor tyrosine
kinase (RTK) was identified as a familial predisposition gene for the
development of neuroblastoma [1]. This study was further supported
by four independent reports of additional activating ALK mutations
in both familial and somatic neuroblastomas [2–5]. Neuroblastoma
is a neural crest–derived embryonal tumor of the postganglionic sym-
pathetic nervous system. Further, it is the most common single solid
tumor of childhood with the worst prognosis, constituting almost
6% of diagnosed tumors and more than 9% of all deaths [6]. The
origin of these tumors remains unknown in most cases, although a
number of familial cases have recently been associated with muta-
tions of the ALK gene [1,5]. Neuroblastomas show heterogeneous
biologic and clinical features and, whereas a subset may undergo
spontaneous differentiation or regression with little or no therapy,
the majorities are difficult to cure with current modalities. The
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ALK RTK was first described in the mid-1990s, and aberrant ALK pro-
tein activity is now implicated in a range of nonhematopoietic, hema-
topoietic, as well as neuroendocrine tumors (for review, see Palmer et al.
[7]). At this point, there are no clinically approved treatments of aber-
rant regulated or oncogenic ALK expression, although recent studies
provide an optimistic view of Crizotinib, a small ALK and c-Met inhib-
itor in ALK-positive non–small cell lung cancer and inflammatory
myofibroblastic tumor [8–10]. One possible positive offshoot is the
potential use of Crizotinib to treat neuroblastoma patients [7].
In this study, we have investigated the described ALKI1250T mu-
tation discovered in a neuroblastoma patient [1]. This mutation had
not previously been described in either the SNP database (dbsSNP;
http://www.ncbi.nlm.nih.gov/projects/SNP/) or in the somatic mu-
tation database (COSMIC; http://www.sanger.ac.uk/genetics/CGP/
cosmic) [1]. The ALKI1250T mutation was present in the matched
germ line DNA, raising the possibility of hereditary predisposition
[1]. The original in silico analysis predicted ALKI1250T to be an acti-
vating mutation in ALK [1]. During 2010, the crystal structure of
the ALK kinase domain was described by two groups [11,12], in
which the ALKI1250T catalytic loop mutation was described as pro-
moting oncogenesis by altering the substrate binding to become a
gain-of-function mutation [11], further reinforcing the notion that
ALKI1250T is an activated mutant. However, to our own surprise and
in contrast to previous predictions, we clearly observe that rather than
being a gain-of-function mutation, the ALKI1250T mutant is actually a
kinase-dead RTK.
Materials and Methods
Generation of Human and Mouse ALK Mutant Constructs in
Cells and Drosophila
Construction of the mouse 3761 T→C point mutation, correspond-
ing to the mouse I1254T mutation, and the human 3749 T→C,
corresponding to the human I1250T mutation was performed using
QuickChange Site-Directedmutagenesis kit (Stratagene, [CedarCreek,
TX] according to the manufacturer’s instructions) with the following
primers: mouse 5′-CACTTTATCCACCGGGATACTGCTGCTA-
GAAACTG-3′ and 5′-CAGTTTCTAGCAGCAGTATCGGCGTG-
GATAAAGTG-3′ and human 5′-ACCACTTCATCCACCGAGA-
CACTGCTGCCAGAA-3′ and 5′-TTCTGGCAGCAGTGT-
CTCGGTGGATGAAGTGGT-3′. All constructs were confirmed by
sequencing from both directions. The mouse ALKI1254T fragment was
ligated into the pTTP vector, described in Schonherr et al. [13], resulting
in the pTTPmALK I1254T plasmid. Human pcDNA wild-type and
F1174S ALK have been described [14]. The human ALKI1250T frag-
ment was ligated into full-length human ALK in both pTTPhALK and
pcDNA3(hALK) [14].
Antibodies and Inhibitors
The following antibodies were used: anti–pan-ERK (1:5000) was
purchased from BD Transduction Laboratories (Franklin Lakes, NJ), and
the anti–p-ERK was from Cell Signaling Technology (Danvers, MA). The
activating monoclonal antibodies 46 and 31 (mAb46 and 31) have been
described previously [14,15]. Monoclonal Ab no. 153 was produced in
the laboratory against the extracellular domain of ALK in similar manners
as described [15]. The anti–phosphotyrosine antibody 4G10 was from
Upstate Biotech (Lake Placid, NY). Organelle marker antibodies, anti–
GRP78/BiP rabbit antibody (ab21685) and anti–GM130 rabbit antibody
(ab52649), were obtained from Abcam (Cambridge, United Kingdom).
Cy2-labeled goat antimouse IgG and Cy3-labeled goat antirabbit IgG
were from GE Healthcare (Uppsala, Sweden).
The horseradish peroxidase–coupled secondary antibodies goat
antirabbit IgG and goat antimouse IgG were from Thermo Scientific
(Waltham, MA). The ALK-specific inhibitor NVP-TAE684 has been
described previously [13,16].
Cell Lysis, Immunoprecipitation, and Western Blot Analysis
Briefly, both mouse and human PC12ALKI1250T cells were induced
with doxycycline and serum starved for 20 hours. PC12mALKwt cells
were additionally stimulated with 1 μg/ml of the activating mAb46 for
30 minutes [13,15,17]. Precleared cell lysates were analyzed on SDS/
PAGE, followed by immunoblot analysis with the indicated antibodies.
ALK downstream activation was detected by p-ERK, and pan-ERKwas
used to show equal loading. ALK-phosphorylation was detected by the
4G10 antibody. Cell lysis, immunoprecipitation, and immuno-
blot analysis were performed according to the protocols described in
Schonherr et al. [13].
Neurite Outgrowth Assay
Both PC12mALKwt and PC12mALKI1254T cells were seeded
sparsely in six-well plates, and ALK expression was induced by doxy-
cycline. PC12mALKwt cells were stimulated with 1 μg/ml mAb46.
Quantification of neurite outgrowth in the cells was carried out as
described [15]. Experiments were performed in triplicates, and each
sample within an experiment was performed in duplicate. For human
ALK, 2 × 106 PC12 cells were transfected by electroporation in an
Amaxa electroporator (Amaxa, Cologne, Germany) using 0.8 μg of
pcDNA3-hALKwt and 0.8 or 1.6 μg of pcDNA3-hALKI1250T and
0.5 μg of pcEGFPN1 (Clontech, Mountain View, CA) and 100 μl of
Ingenio electroporation solution (Mirrus Bio LCC, Madison, WI). After
transfection, cells were transferred to Dulbecco modified Eagle medium
(DMEM) supplemented with 7% horse serum and 3% fetal bovine se-
rum, thereafter seeded into 24-well plates together with 1 μg/ml mAb31.
Two days after transfection, the fraction of GFP-positive and neurite-
carrying cells versus GFP-positive cells was estimated under a Zeiss
Axiovert 40 CFL microscope (Carl Zeiss, Stockholm, Sweden). To be
judged as a neurite-carrying cell, the neurites of the cell had to reach at
least twice the length of the diameter of a normal cell body.
Transformation Assay
Low-passage number NIH 3T3 cells (ATCC, Manassas, VA) were
transfected with Lipofectamine 2000 according to the manufacturer’s
protocol. Briefly, 4.5 × 104 cells, seeded the day before into collagen-
coated 12-well plates, were transfected for 6 hours with 0.55 μg of
pcDNA3 containing hALKwt, hALKI1250T, or hALKF1174S DNA and
1.4 μl of Lipofectamine 2000 in 0.3 ml of Opti-MEM. Twenty-four
hours after transfection, three fifths of the cells from each well were
transferred to wells in 12-well plates and kept in DMEM (10% fetal
calf serum [FCS] and 0.5 mg/ml G418) until the cells reached conflu-
ence. Thereafter, cells were kept in DMEM (5% FCS and 0.25 mg/ml
G418) for another 10 days.
Cell Culture and Immunofluorescence
CLB-GE neuroblastoma cell line was grown as described [5].
HEK293 cells were grown in DMEM containing 10% heat-inactivated
FCS on collagen-coated coverslips. According to the manufacturer’s
protocol, pcDNA3-ALK(wt or I1250T) was transfected using Lipo-
fectamine (Invitrogen, Carlsbad, CA). After 24 hours of incubation,
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cells were fixed with 4% paraformaldehyde/DMEM for 30 minutes at
37°C and incubated with 10 mM NH4Cl/phosphate-buffered saline
(PBS) for 15 minutes at room temperature. Then, cells were blocked
by 5% goat serum and 0.3% Triton X-100 in PBS for 2 hours at room
temperature and further incubated with primary antibodies (anti–
human ALK mouse mAb153 at 1 μg/ml and anti–GRP78 rabbit anti-
body diluted 1:200/anti–GM130 rabbit antibody diluted 1:200) in PBS
containing 1% bovine serum albumin and 0.3% Triton X-100 at 4°C
overnight. After rinsing three times with PBS, cells were incubated with
fluorescence-labeled secondary antibodies (Cy2-labeled antimouse IgG
and Cy3-labeled antirabbit IgG both at 1:1000 dilution) for 2 hours at
room temperature. After rinsing with PBS, coverslips were mounted on
slides with Fluoromount G (Southern Biotechnology Associates, Inc,
Birmingham, AL). For nonpermeabilized cells, cells were incubated
without Triton X-100. Immunostained cells were visualized with a Zeiss
fluorescence microscope equipped with an Apotome (Carl Zeiss). Images
were acquired and processed by using Zeiss AxioVision 4.8 (Carl Zeiss).
Generation of Human ALK Mutant Transgenic Constructs
for Drosophila melanogaster
Before ligation of human ALKI1250T from pcDNA3 into the Dro-
sophila expression vector pUAST, an 898-base pair fragment preced-
ing the translation start was removed to increase expression efficiency
in the Drosophila system as described [14], and details are available
on request. All three constructs were subsequently subcloned into
the EcoRI-NotI site of the pUAST Drosophila vector, and the result-
ing constructs were verified by DNA sequencing analysis. Trans-
genic constructs were used for the generation of transgenic fly strains
(BestGene, Inc, Chino Hills, CA). The following stocks were used:
w1118 (stock number 5905; Bloomington, IN) and pGMR-Gal4 (stock
number 9146; Bloomington). The transgenic fly strains UAS-ALK wt,
UAS-ALK F1174L, and UAS-ALK R1275Q were generated as described
above. Expression in the eye, immunoblot analysis, and fluorescent
and electron microscopy of wild-type and mutant ALK proteins were
carried out as described in Martinsson et al. [14].
Results
ALK I1250T Is Not a Gain-of-Function RTK in
Cell Culture Systems
To investigate the intrinsic activity of the mouse ALKI1254T mutant,
which is equivalent to human ALKI1250T, we used an inducible PC12
cell culture system for the clonal expression of both wild-type ALK and
mouse ALKI1254T mutant (Figure 1A). On stimulation with an agonist
monoclonal antibody (mAb46), the doxycycline-expressed mouse wild-
type ALK RTK becomes tyrosine phosphorylated (Figure 1A, top two
panels, compare lane 3 with lanes 2 and 1). Further, the stimulated re-
ceptor also activates/phosphorylates downstream targets, such as Erk,
and the activation/phosphorylation of Erk is not detected when the
wild-type ALK receptor is not stimulated (Figure 1A, lower two panels,
compare lane 3 with lanes 2 and 1). However, the expression of the
putative gain-of-function mouse ALKI1254T shows no activation of
Erk and no auto/transphosphorylation activity of the receptor was ob-
served either on induction of expression only or on stimulation of
mouse ALKI1254T RTK with mAb46 agonist antibody (Figure 1A,
compare lanes 4, 5, and 6).
A sensitive functional readout for activity in PC12 cells is the ability
to induce neurite outgrowth. We and others have previously shown
that activation of both human and mouse ALK triggers differentiation
Figure 1. Mouse ALKI1254T mutant is not constitutively active and
cannot be activated. (A) To investigate ALK signaling, PC12 cells
were induced for expression of either mALKwt or mALKI1254T mu-
tant with 1 and 2 μg/ml doxycycline, respectively, serum starved
for 20 hours before stimulation with 1 μg/ml mAb46 for 30 minutes
[14]. Precleared cell lysates were analyzed on SDS-PAGE, followed
by immunoblot analysis with the indicated antibodies. ALK down-
stream activation was detected by phospho-ERK and pan-ERK
was used to show equal loading. Tyrosine phosphorylation of ALK
was visualizedwith 4G10 beads immunoprecipitation and p-ALKwas
detected by anti-ALK immunoblot analysis. (B) Neurite outgrowth
assay. PC12mALK cells induced for mALK expression were stim-
ulated with 1 μg/ml mAb46. After 48 hours, neurite-bearing cells
were scored as described before [14]. The experiment was carried
out in triplicate, and each sample within an experiment was per-
formed in duplicate. Statistical significance was obtained by Stu-
dent’s t test. P values between unstimulated and stimulated
mALKwt as well as between stimulated mALKwt and stimulated
mALKI1254T were less than .01. (C) Representative figures of neurite
outgrowth of PC12mALK cells.
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of PC12 cells into sympathetic-like neurons, a process that is charac-
terized by extension of neurites [13]. The expression of both wild-type
ALK and ALKI1254T was induced in PC12 cells by the addition of
doxycycline (Figure 1, B and C ). The activating antibody mAb46
was added simultaneously to cells expressing wild-type and also to cells
expressing the ALKI1254T mutant. Images were acquired 48 hours after
incubation in the presence of doxycycline and mAb46 (Figure 1C). In
agreement with our earlier results, we observed a differentiation of
PC12 cells expressing the wild-type ALK on stimulation (Figure 1,
B and C ). However, we observed that expression of the ALKI1254T
mutant is unable to mediate neurite outgrowth within 48 hours, even
on cell stimulation with the activating mAb46 (Figure 1, B and C ).
Importantly, the expression of wild-type ALK in the absence of activat-
ing antibodies is unable to mediate neurite outgrowth (Figure 1, B and
C). This lack of neurite outgrowth activity observed with ALKI1254T
is in contrast to the robust neurite outgrowth achieved on stimulation
of mouse ALK and wild-type human ALK (Figure 1, B and C ; data
not shown).
Mouse and human ALK are very similar, displaying 87% overall
homology at the protein level. Indeed, within the kinase domain,
they differ at very few amino acids; however, one major difference
between mouse and human ALK is at Tyr1604, which is lacking
in the mouse ALK protein and has been implicated in tumor progres-
sion in human ALK [18]. To confirm our unexpected results with
the mouse ALKI1254T mutant, we investigated the human ALKI1250T
mutant. On transfection and stimulation of the wild-type human
ALK, we observed both an auto/transphosphorylation of the receptor
and stimulation of the Erk pathway (Figure 2A, compare lane 4 with
3). Similar to our findings with mouse ALKI1254T, stimulation of the
human ALKI1250T neither mediates phosphorylation of the receptor
nor could any Erk activity be detected (Figure 2A, compare lanes 6
and 7 with lanes 3 and 4). As a positive control for gain-of-function
activity, we used the human ALKF1174S mutation, which is a strongly
activating neuroblastoma mutation and which is autophosphorylated
and stimulates ERK activity on expression in a ligand-independent
manner (Figure 2A, lane 5) [14]. Further, human ALKI1250T was
unable to induce neurite outgrowth, in contrast to both human
ALKF1174S and the stimulated wild-type ALK receptor (data not
shown). Similar experiments with stable clones of PC12 cells were
performed with the human wild-type ALK, the activating human
ALKF1174S, and human ALKI1250T with identical results (Figure W1).
Thus, it is clear that both mouse ALKI1254T mutant and human
ALKI1250T display no detectable tyrosine phosphorylation activity.
Further, they are unable to activate Erk or to induce neurite outgrowth
in vitro cell culture systems. We next investigated whether the human
ALKI1250T displayed transforming potential. NIH 3T3 cells were trans-
fected with human ALKI1250T in comparison with wild-type ALK and
ALKF1174S gain-of-function mutation. The expression of human
ALKF1174S mediates foci of transformed cells over the background
monolayer, whereas overexpression of the wild-type human ALK recep-
tor and ALKI1250T is unable to mediate foci formation (Figure 2B).
Thus, both human ALKI1250T and the equivalent mouse ALK mutant
show no intrinsic transforming activity.
Then we cotransfected wild-type human ALK together with the
ALKI1250T mutant. In this analysis, ALKI1250T exhibits a dominant-
negative effect, reducing the phosphorylation of ERK on stimulation
of wild-type ALK on stimulation. The phosphorylation of Erk is
two-fold lower compared with stimulation of Erk in cells only trans-
fected with wild-type ALK over time (Figure 2C , compare lanes 2
and 10 with lane 6 or lanes 3 and 11 with lane 7, or lanes 4 and 12
with lane 8). This result is reinforced by similar findings in four inde-
pendent experimental setups. First, a reduction of Erk phosphoryla-
tion is observed on cotransfection of constitutively active ALKF1174S
together with the ALKI1250T mutant (Figure W2A). Second, transfec-
tion of FLAG-tagged ALKI1250T into the neuroblastoma cell line CLB-
GE, which expresses the ALKF1174V mutation [5], results in a two-fold
decrease in ERK phosphorylation compared with untransfected CLB-
GE cells (Figure W2B). As a control, the ALK inhibitor NVP-TAE-
684 was added to the CLB-GE cell line, abrogating all ALK-mediated
ERK phosphorylation (FigureW2B, compare lanes 2 and 4 with lanes 1
and 3). Third, on transient transfection of FLAG-tagged ALKI1250T
alone or together with untagged ALK, we observed that FLAG-tagged
ALKI1250T is not detectably tyrosine phosphorylated, either on amino
acid Y1604 or when analyzed with tyrosine specific antibody 4G10,
even on stimulation of wild-type ALK (Figure W2C , compare lane 2
with 4). Finally, using the PC12 cell neurite out growth assay to
cotransfection either human wild-type ALK alone, or together with
ALKI1250T , followed by stimulation of ALK leads to a decrease in neu-
rite outgrowth potential of ALK in the presence of the ALKI1250T
mutant (Figure 2D). Similar results are observed if the activating
ALKF1174S is transfected togetherwithALKI1250T (data not shown).Taken
together, these six independent experiments argue that the expression
of ALKI1250T has the potential to act as a dominant-negative receptor
when expressed together with catalytically competent ALK receptors.
Ectopically Expressed Human ALK I1250T Is Inactive in
Drosophila melanogaster
Molecular signaling pathways in Drosophila melanogaster share
conservation of core components with vertebrate pathways. The
Drosophila ALK RTK mediates activation of the ERK pathway in re-
sponse to the ligand Jeb in the developing visceral mesoderm, a sig-
naling pathway that is crucial for the formation of the fly gut in vivo
([7]). For simplicity, we chose to ectopically express wild-type human
UAS-ALK in the Drosophila eye using the pGMR-Gal4 driver line,
which directs protein expression in the developing photoreceptors of
the eye. This provides a sensitive assay for perturbed signaling in vivo,
and indeed ectopic expression of wild-type human ALK does not
result in any obvious phenotype in the adult fly eye (Figure 3B)
and is similar to controls (Figure 3A). Expression of the human
ALK protein was confirmed both by immunohistochemical and
immunoblot analysis of developing eye discs (Figure 3H ). Thus, the
wild-type ligand-dependent human ALK RTK does not seem to be ac-
tivated by endogenousDrosophila ligands, providing a clean background
in which to analyze the activating potential of putative activating mu-
tants of the human ALK as identified in neuroblastoma patients.
Given the clean phenotypic background observed with overexpres-
sion of the wild-type human ALK, we proceeded to investigate the
in vivo signaling potential of the putative activated hALKI1250T mutant
in theDrosophila system. As would be expected from a gain-of-function
ALKmutation, ectopic expression of ALKF1174S leads to the destruction
of normal tissue morphology in the developing fly eye (Figure 3D). The
destructive effects of ectopic expression of human ALKF1174S in the fly
eye are already observed during third instar larval stages, where the
organization of ommatidial units in the developing fly eye is clearly
disrupted (Figure 3G ). However, ectopic expression of activated
hALKI1250T mediates no such phenotype and shows similar wild-type
phenotype as expression of wild-type human ALK and controls (Fig-
ure 3, compare C and F with B and E). Because no human ALK ligand
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is present during the development of the Drosophila eye, as evidenced
by the lack of phenotype observed on the expression of wild-type hu-
man ALK, these results confirm that the human ALKF1174S mutant
is indeed a ligand-independent activating mutant of the ALK RTK
in vivo. In stark contrast, the lack of rough eye phenotype observed
on the expression of human ALKI1250T suggested that it is not a gain-
of-function ligand-independent ALK mutant as previously predicted.
Wild-type ALK and ALK I1250T Are Localized on the
Cell Surface
Finally, we asked if the ALKI1250T mutation is localized differently
compared with the wild-type receptor. Analysis in the Drosophila
system (Figure 3, E and F ) suggests that, like wild-type hALK,
hALKI1250T is localized on the cell membrane. To investigate this
further, we asked whether the cellular localization of the ALKI1250T
mutation is different fromwild-type inmammalian cells.Here,HEK293
cells were transiently transfected with either human ALKI1250T or wild-
type ALK. Human ALKI1250T protein is expressed on the plasma mem-
brane in a manner similar to wild-type ALK (Figure 4). Previous reports
have shown that ALK protein also localizes intracellularly to structures
such as the endoplasmic reticulum and Golgi apparatus [19]. We also
find that the ALKI1250T protein shows similar subcellular localization
to wild-type ALK, being found in the endoplasmic reticulum (Figure 4,
compare A and A″ with C and C″) and weakly in the Golgi apparatus
(data not shown) in addition to plasmamembrane localization (Figure 4,
compare BwithD). Thus, this indicates that both receptors are expressed
on the cell surface, providing ALKI1250T with the opportunity to act as a
dominant-negative receptor when expressed together with wild-type or
gain-of-function ALK receptor.
Discussion
Here we show that the postulated gain-of-function human ALKI1250T
shows no detectable biochemical and transforming activity. We show
that this is also true for the mouse ALKI1254T mutant. In agreement,
the human ALKI1250T mutation is unable to induce a rough eye pheno-
type inDrosophila, in contrast with gain-of-functionALKmutations [14].
Recently, the crystal structure of ALK was reported, which facil-
itates our understanding of the mechanistic basis of ALK mutations
identified in neuroblastoma [11,12]. With the benefit of experimen-
tal data demonstrating that ALKI1250T is a kinase inactive mutant, we
can exploit the elegant structural studies of Bossi et al. [11] and Lee
et al. [12] to suggest a mechanistic explanation. As discussed before,
the mutation at amino acid position 1250 is in the catalytic loop of
the kinase domain (Figures 5A and W3). Position 1250 of ALK is
Figure 3. ALKI1250T is not an activating mutation of ALK in Dro-
sophila. UAS-ALK transgenes are ectopically expressed in the
eye tissue using the eye-specific GMR-GAL4 driver. (A) Wild-type
eye. (B) ALKwt expression does not affect eye organization, in-
dicating the absence of an activating ligand in the fly. (C) The ex-
pression of ALKI1250T does not cause a rough eye phenotype,
indicating that ALKI1250T is not a gain-of-function mutation. (D)
ALKF1174S expression causes rough eye phenotype, illustrating
that ALKF1174S is a ligand-independent activating mutation. (E–G)
Transgene expression is confirmed in larval eye discs by antibody
staining against human ALK. (E) Photoreceptor organization is
unaffected by expression of ALKwt. (F) ALKI1250T does not affect
the photoreceptor pattern. (G) ALKF1174S expression disrupts photo-
receptor organization. (H) Western blot analysis of protein lysates of
fly heads from flies in which the transgenes have been expressed
using the eye tissue-specific driver GMR-GAL4. Protein expression
is confirmed by antibody staining against human ALK. Controls are
wild-type flies (W1118) and the driver line GMR-GAL4 alone. Positive
control is a PC12 cell lysate sample in which hALK transgene expres-
sion has been induced by doxycycline.
Figure 2. Human ALKI1250T mutant is not constitutively active and cannot be activated. (A) To study human ALK signaling, PC12 cells
were transiently transfected with 2 μg of pcDNA3.1 as a control and pcDNA3.1-hALKI1250T as well as 0.8 μg of pcDNA3-hALKwt and
hALKF1174S followed by starvation for 48 hours before stimulating with 1 μg/ml of the activating mAb46 for 30 minutes [14]. Lysates were
analyzed on SDS-PAGE, followed by immunoblot analysis with the indicated antibodies. ALK downstream activation was detected by
phospho-ERK and pan-ERK was used to show equal loading. ALK phosphorylation was detected by 4G10-IP, followed by immunoblot
analysis with an ALK antibody. (B) Focus formation assay where low-passage NIH 3T3 cells were seeded in six-well plates the day before
transfection with 1.5 μg of each plasmid, as described in Martinsson et al. [14]. Colonies visible by the naked eye were scored in trip-
licates. Lower panel: Data shown are the average of three independent experiments. Statistical significance was obtained by Student’s
t test. P values between hALKwt and hALKF1174S as well as between hALKF1174S and hALKI1250T were less than .01. (C) PC12 cells were
transiently transfected with 2 μg of DNA in total (for cotransfections, 0.8 μg of pcDNA3.1 as a control, 0.8 μg of pcDNA3.1-hALKwt and
1.2 μg of pcDNA3.1-hALKI1250T were applied) as in A. The transfected cells were then serum starved and treated with 1 μg/ml of the
activating mAb46 for the indicated times. Lysis, immunoprecipitation, and immunoblot analysis were performed as described [13]. ALK
downstream activation was detected by phospho-ERK, and pan-ERK was used to show equal loading. To show a decrease of hALKwt-
mediated ERK phosphorylation by cotransfection with hALKI1250T, the bands for p-ERK and pan-ERK were densitometrically quantified.
Relative band intensities from three different experiments are shown as mean ± SD. (D) PC12 cells were transfected with the indicated
amounts of hALKwt and hALKI1250T as described above. The neurite outgrowth assay is similar as to Figure 1B. Statistical significance
was obtained by Student’s t test. P values between activated hALKwt and 0.8 μg of hALKI1250T or 1.6 μg of hALKI1250T were less than .01.
Translational Oncology Vol. 4, No. 4, 2011 ALKI1250T Mutation in NB Tumor Schönherr et al. 263
Figure 4. Subcellular localization of the ALKI1250T kinase-dead mutant. Immunofluorescence for hALK wild-type– (A and B) or I1250T- (C
and D) expressing HEK293 cells. Cells were immunostained with anti-ALK antibody (A, A″ and C, C″) and anti-GRP78 antibody as an ER
marker (A′, A″ and C′, C″). (A″ and C″) Merged pictures. (A and C) Detergent permeabilized cells. (B and D) Nonpermeabilized cells. ALK
proteins are localized on the cell surface (B and D), the ER (A and C), and weakly at the Golgi (data not shown).
Figure 5. Model of the catalytic domain of ALK containing the I1250T mutation. (A) Model of the N-terminal kinase domain of ALK (PB
no. 3LCS). (B) Model of the hydrophobic pocket of human wild-type ALK. (C) Model of the hydrophobic pocket of human ALK with the
I1250T mutation.
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highly conserved in the active site of protein kinases (Figure 5A)
[11,12]. These large, hydrophobic amino acids are part of the con-
served catalytic loop sequence HRDI/LAARN, which also influence
the hydrophobic spine [20]. The ALK crystal structures have shown
that this residue mediates contact with a conserved hydrophobic
patch composed of residues from helix 1 and 2 (I1233, I1268,
F1315) of the C-lobe (Figure 5B). Hence, the hydrophobic residue
of the HRDI/LAARN motif acts to anchor the catalytic loop to es-
tablish the correct positioning in respect to the DFG loop and ATP.
The I1250T mutation results in a much smaller side chain at this
position and introduces a polar functionality (the hydroxyl group
of the threonine side chain) into this hydrophobic interface, which
probably results in weakening of the hydrophobic contact/anchorage
(Figure 5C ) presumably leading to the destabilization of the entire
active site of ALK. Another possibility for the influence of the
I1250T mutation on the catalytic activity of ALK is the close prox-
imity of the side chain of I1250 to H1247. The I1250T mutation
could modulate the interaction of the side chain of H1247 with the
carbonyl oxygen of D1270 from the DFG motif with a possible de-
stabilizing effect impairing the activation of the kinase. Our struc-
tural view on the ALK1250T, strengthened by experimental evidence
is in stark contrast to the earlier descriptions by Mosse et al. [1] and
Bossi et al. [11], which describe the ALKI1250T catalytic loop mutation
as a gain-of-function mutation promoting oncogenicity.
It is possible that a kinase-dead ALKI1250T might have a biologic/
functional activity in the presence of an activated ALK RTK. Indeed,
a cooperative tumorigenicity mechanism has recently been described
for kinase-dead BRAF in the presence of oncogenic RAS [21]. Fur-
ther, activation of the kinase-dead ALK receptor could occur through
heterologous cross-phosphorylation on tyrosine residues in a ligand-
dependent way by the other wild-type ALK [22,23]. However, the
data thus far would argue that the ALKI1250T acts in a dominant-
negative manner when expressed with active ALK. The implication
of the presence of the ALKI1250T mutant for down-regulation in vivo
is unclear and will require future investigation. However, one could
speculate that such a mutation of one copy of the ALK locus may
have a minor effect in humans because knockouts of ALK in mice
have no gross phenotype and are viable and fertile [24] (B.H. and
R.P., unpublished results), although they do display increased hippo-
campal progenitor proliferation and increased performance in hippo-
campal-associated tasks [25]. Taken together, the results presented
here clearly demonstrate that the novel ALKI1250T mutant is not a
ligand-independent gain-of-function RTK. Thus, the appearance of
the novel ALKI1250T mutant cannot be simply correlated with the
development of aggressive neuroblastoma at the patient level and
should be considered accordingly.
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Figure W1. Human ALKI1250T mutant is not constitutively active
and cannot be activated. The stable PC12 Tet-on clones PChALK
containing either hALKwt, hALKF1174S, or hALKI1250T mutation were
generated. To investigate human ALK signaling, 1 × 106 cells were
induced for the expression of hALKwt, hALKF1174S, or hALK con-
taining the I1250T mutant with 2 μg/ml doxycycline. The cells were
induced and serum starved for 20 hours before stimulation with
1 μg/ml mAb31 for 30 minutes. Precleared cell lysates were ana-
lyzed on SDS-PAGE, followed by immunoblot analysis with the in-
dicated antibodies. Pan-ERK was used to show equal loading. To
detect tyrosine phosphorylation of ALK, the cell lysates were incu-
bated with 4G10 beads (catalog no. 16-101; Upstate), and p-ALK
was detected by anti-ALK immunoblot analysis. The mutated hALK
fragment was digested with BlpI-FseI restriction enzymes and li-
gated into the BlpI-FseI sites (human ALK, position 4143 and
5309) of the full-length human ALK in both pTTPhALK [14]. Stable
PC12 Tet-on human ALK and ALKF1174S have been described [13].
Figure W2. The human ALKI1250T mutant cannot be transactivated
by human ALKwt. (A) About 2× 106 PC12 cells per sample were tran-
siently transfected with 2 μg of DNA in total (for cotransfections,
0.8 μg of pcDNA3.1 as a control, 0.8 μg of pcDNA3.1-hALKF1174S,
and 1.2 μg of pcDNA3.1-hALKI1250T were applied) using Ingenio
Electroporation Solution (Mirus Bio LLC, Madison, WI) and the
Amaxa Electroporator (Amaxa Biosystems) according to the manu-
facturers’ protocol. The transfection efficiency was approximately
60% to 80%. The transfected cells were then serum starved and har-
vested after 24 and 48 hours, respectively. Precleared cell lysates
were analyzed on SDS-PAGE, followed by immunoblot analysis with
the indicated antibodies. ALK downstream activation was detected
by p-ERK, and pan-ERK was used to show equal loading. To show a
decrease of hALKwt-mediated ERK phosphorylation by cotransfec-
tion with hALKI1250T, the bands for p-ERK and pan-ERK were densi-
tometrically quantified. Relative band intensities from three different
experiments are shown asmean± SD. (B) About 2× 105 cells of the
neuroblastoma cell line CLB-GE were transiently transfected with
FLAG-hALKI1250T using Lipofectamine 2000 (Invitrogen) according
to the manufacturer’s protocol. The cells were serum starved and
treatedwith 100 nMNVP-TAE684 for 24 hours. Preclearedcell lysates
were analyzed on SDS-PAGE, followed by immunoblot analysis with
the indicated antibodies. ALK downstream activation was detected
by p-ERK, and pan-ERK was used to show equal loading. To show a
decrease of hALKwt-mediated ERK-phosphorylation by cotransfection
with hALKI1250T, the bands for p-ERK and pan-ERK were densitomet-
rically quantified. Relative band intensities from three different experi-
ments are shown as mean ± SD. (C) About 2 × 106 PC12 cells per
sample were transiently transfected with 2 μg of pcDNA3.1 as a con-
trol, 1.2 μg of pcDNA3.1-hALKI1250T or FLAG-hALKI1250T, as well as
0.8 μg of pcDNA3.1-hALKwt or FLAG-hALKwt using Ingenio Electro-
poration Solution (Mirus BIO LLC) and the Amaxa Electroporator
(Amaxa Biosystems) according to the manufacturers’ protocol. The
transfected cells were then serum starved for 24 hours before stim-
ulation with 1 μg/ml of the activating mAb46 for 30 minutes. The
FLAG-tagged human ALK variants were immunoprecipitated by FLAG
antibody (Sigma, St Louis, MO), followed by SDS-PAGE analysis
and immunoblot analysis with the indicated antibodies. ALK activa-
tion and tyrosine phosphorylation were detected by pY1604 and
4G10 antibodies.
Figure W3. Sequence alignment of catalytic domains of RTKs. Sequence alignment of some catalytic domains of human insulin recep-
tor (Swiss-Prot P096213), human c-Met Receptor (Swiss-Prot P08581), and both human (Swiss-Prot Q9UM73) and mouse ALK (Swiss-
Prot P97793). The HRD motif, the autophosphorylated tyrosines of the YxxxYY motif and the hinge region (I before the DFG motif), are
marked in bold. The DL/IAARN motif is highlighted in bold and underlined. The DFG motif in the activation loop is in italic and the
position 1250 for the I→T mutation is marked by an asterisk. The conserved catalytic D is marked by an arrow. The amino acids forming
the hydrophobic pocket are highlighted in red.
